4.7 Article

MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative

期刊

ALZHEIMERS & DEMENTIA
卷 15, 期 10, 页码 1322-1332

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2019.06.4948

关键词

Mild cognitive impairment; Reversion; Diagnostic criteria; Stability; Neuropsychology; Alzheimer's disease

资金

  1. NIH [R01 AG049810, K24 AG026431, P50 AG005131]
  2. Alzheimer's Association [AARF-17-528918, AARG-17-500358]
  3. U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service [2 1IK2 CX001415-01A1]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. AbbVie
  9. Alzheimer's Association
  10. Alzheimer's Drug Discovery Foundation
  11. Araclon Biotech
  12. BioClinica, Inc.
  13. Biogen
  14. Bristol-Myers Squibb Company
  15. CereSpir, Inc.
  16. Cogstate
  17. Eisai Inc.
  18. Elan Pharmaceuticals, Inc.
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd
  22. Fujirebio
  23. GE Healthcare
  24. IXICO Ltd.
  25. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  26. Johnson & Johnson Pharmaceutical Research & Development LLC.
  27. Lumosity
  28. Lundbeck
  29. Merck Co., Inc.
  30. Meso Scale Diagnostics, LLC.
  31. NeuroRx Research
  32. Neurotrack Technologies
  33. Novartis Pharmaceuticals Corporation
  34. Piramal Imaging
  35. Servier
  36. Takeda Pharmaceutical Company
  37. Transition Therapeutics
  38. Canadian Institutes of Health Research
  39. Genentech, Inc.
  40. Pfizer Inc.

向作者/读者索取更多资源

Introduction: The low mild cognitive impairment (MCI) to cognitively normal (CN) reversion rate in the Alzheimer's Disease Neuroimaging Initiative (2-3%) suggests the need to examine reversion by other means. We applied comprehensive neuropsychological criteria (NP criteria) to determine the resulting MCI to CN reversion rate. Methods: Participants with CN (n = 641) or MCI (n = 569) were classified at baseline and year 1 using NP criteria. Demographic, neuropsychological, and Alzheimer's disease biomarker variables as well as progression to dementia were examined across stable CN, reversion, and stable MCI groups. Results: NP criteria produced a one-year reversion rate of 15.8%. Reverters had demographics, Alzheimer's disease biomarkers, and risk-of-progression most similar to the stable CN group and showed the most improvement on neuropsychological measures from baseline to year 1. Discussion: NP criteria produced a reversion rate that is consistent with, albeit modestly improved from, reversion rates in meta-analyses. Reverters' biomarker profiles and progression rates suggest that NP criteria accurately tracked with underlying pathophysiologic status. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据